

DAFTAR PUSTAKA

1. Lin SU, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. *Liver Int.* 2020;40(9):2082-2089.
2. Lekakis V, Papatheodoridis G V. Natural history of metabolic dysfunction-associated steatotic liver disease. *Eur J Intern Med.* 2024;122(11):3-10. doi:10.1016/j.ejim.2023.11.005
3. Ghazanfar H, Javed N, Qasim A, et al. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review. *Cancers (Basel).* 2024;16(6):1-17. doi:10.3390/cancers16061214
4. Shan T, Li X, Yan M, Pan X. Evaluation of prognosis and risk of death by neutrophil/lymphocyte ratio, C-reactive protein/albumin ratio and plasma D-dimer in patients with pulmonary thromboembolism. *Int J Gen Med.* Published online 2021:9219-9225.
5. Tripodi A, Lombardi R, Primignani M, La Mura V, Peyvandi F, Fracanzani AL. Hypercoagulability in patients with non-alcoholic fatty liver disease (NAFLD): causes and consequences. *Biomedicines.* 2024;12(1):249.



6. Putri RA, Diansyah MN, Ashariati AA, et al. Diathesis Hemorrhagic, Coagulation and Fibrinolytic System. *Biomol Heal Sci J.* 2022;5(1):54-61. doi:10.20473/bhsj.v5i1.35280
7. Virović-Jukić L, Stojsavljević Shapeski S, Forgač J, Kukla M, Mikolašević I. Non-alcoholic fatty liver disease—a procoagulant condition? *Croat Med J.* 2021;62(1):25-33.
8. Kim CY, Kim N, Roh JH. Association of nonalcoholic fatty liver disease and venous thromboembolic disease in healthy adults in Korea: a nationwide study. *Sci Rep.* 2023;13(1):1-10. doi:10.1038/s41598-023-42963-9
9. Ogresta D, Mrzljak A, Berkovic MC, Bilic-Curcic I, Stojsavljevic-Shapeski S, Virovic-Jukic L. Coagulation and endothelial dysfunction associated with NAFLD: current status and therapeutic implications. *J Clin Transl Hepatol.* 2022;10(2):339.
10. Mariani, Hariman H, Soeroso NS. Hypercoagulability in patients with lung cancer undergoing chemotherapy. *Indoneisan J Clin Pathol Med Lab.* 2015;21(3):21-30.



I, Fomina LL. Comparative physiological aspects of plasma of some commercial fish species. *Egypt J Aquat Biol Fish.* :239-242. doi:10.24425/jwld.2022.141578

12. Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. *Clin Res Hepatol Gastroenterol*. 2021;7(6):99. doi:10.11648/j.ejcbbs.20210706.13
13. Bae SDW, George J, Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. *Chin Med J (Engl)*. 2022;135(5):547-556.
14. Boccata A, Andreetto L, D'Ardes D, et al. From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications. *Biomedicines*. 2023;11(3):883.
15. Li Q, Huang C, Xu W, Hu Q, Chen L. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease. *Medicine (Baltimore)*. 2020;99(23):e20616.
16. Gale AJ. Continuing education course# 2: current understanding of hemostasis. *Toxicol Pathol*. 2011;39(1):273-280.
17. Chaudhry R, Usama SM, Babiker HM. Physiology, coagulation pathways. Published online 2018.



roa R, Palta A. Overview of the coagulation system. *Indian* 2014;58(5):515-523.

19. Krzych LJ, Czempik PF. Association between standard laboratory and functional tests of coagulation in dilutional coagulopathy: an in vitro study. *J Physiol Pharmacol*. 2017;68(4):637-645.
20. Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. *Lab Med*. 2017;48(4):295-313.
21. Macrae FL, Domingues MM, Casini A, Ariens RAS. The (Patho) physiology of Fibrinogen γ' . In: *Seminars in Thrombosis and Hemostasis*. Vol 42. Thieme Medical Publishers; 2016:344-355.
22. Bazhenova N. State of plasma hemostasis in patients with hypertension in combination with non-alcoholic fatty liver disease. *J Educ Heal Sport*. 2018;8(10):294-303.
23. Hickman IJ, Sullivan CM, Flight S, et al. Altered clot kinetics in patients with non-alcoholic fatty liver disease. *Ann Hepatol*. 2009;8(4):331-338.
24. Dhanunjaya Y, Anand U, Anand C V. A study of plasma D-dimer levels in various stages of liver disease. *J Liver*. 2013;2(2):1.
25. Lin F, Zhou H, Cao L, et al. Risk of reduced platelet counts in patients with non-alcoholic fatty liver disease (NAFLD): a prospective cohort study. *Dis Health Dis*. 2018;17:1-7.



26. Yuan Q, Wang H, Gao P, et al. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. *Int J Environ Res Public Health*. 2022;19(4). doi:10.3390/ijerph19042096

27. Guan L, Zhang X, Tian H, et al. Prevalence and risk factors of metabolic-associated fatty liver disease during 2014-2018 from three cities of Liaoning Province: An epidemiological survey. *BMJ Open*. 2022;12(2):1-9. doi:10.1136/bmjopen-2020-047588

28. Johira Y, Nakahara T, Kinami T, et al. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study. *BMC Gastroenterol*. 2023;23(1):1-11. doi:10.1186/s12876-023-02851-y

29. López-Trujillo MA, Olivares-Gazca JM, Cantero-Fortiz Y, et al. Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance. *Clin Appl Thromb*. 2019;25:4-7. doi:10.1177/1076029619888694

30. Kotronen A, Joutsu-Korhonen L, Sevastianova K, et al. Increased factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. *Liver Int*. 2011;31(2):176-183. doi:10.1111/j.1478-0237.5.x



31. Oraby M, Mazoun M, Mohamed AQ, Fawzy M, Abdel-Aziz T, Dahshan I. Study on the Impact of metabolic associated fatty liver disease (MAFLD) on patients with Corona Virus Disease – 2019 (COVID-19). *Benha Med J.* 2023;0(0):0-0. doi:10.21608/bmfj.2023.242125.1924

32. Arepally GM, Padmanabhan A. Heparin-Induced Thrombocytopenia; A Focus on Thrombosis. *Arterioscler Thromb Vasc Biol.* 2021;41(1):141-152. doi:10.1161/ATVBAHA.120.315445

33. Pusparini P, Hidayat A. Hypercoagulable States: Clinical Symptoms, Laboratory Markers and Management. *Front Clin Drug Res.* 2020;4:42-83. doi:10.2174/9789811469558120040004

34. Scully M. Thrombocytopenia in hospitalized patients: Approach to the patient with thrombotic microangiopathy. *Hematology.* 2017;2017(1):651-659. doi:10.1182/asheducation-2017.1.651

35. Chandel A, Patolia S, Looby M, Bade N, Khangoora V, King CS. Association of D-dimer and Fibrinogen With Hypercoagulability in COVID-19 Requiring Extracorporeal Membrane Oxygenation. *J Care Med.* 2021;36(6):689-695.



7/0885066621997039

fatty liver index and blood coagulation markers: a population-based study. *Lipids Health Dis.* 2023;22(1):1-11. doi:10.1186/s12944-023-01854-8

37. Northup PG, Sundaram V, Fallon MB, et al. Hypercoagulation and thrombophilia in liver disease. *J Thromb Haemost.* 2008;6(1):2-9. doi:10.1111/j.1538-7836.2007.02772.x
38. Raffa S, Reverter JC, Seijo S, et al. Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. *Clin Gastroenterol Hepatol.* 2012;10(1):72-78. doi:10.1016/j.cgh.2011.09.010

